Biography
I am a Belarusian-born researcher with a passion for biophysics, nanotechnology, and their intersection with computer science and robotics. After graduating high school with a gold medal and winning the national Olympiad in physics, I earned my Bachelor’s and Master’s degrees in Physics (specializing in Biophysics) from Belarusian State University, graduating with honors in 2015 and 2016. Since 2014, I have been actively involved in biophysics research, with a growing focus on computational approaches in nanotechnology and biophotonics for oncology applications.
In 2019, I completed my Ph.D. in Nanobiotechnology under joint supervision from the University of Lorraine and Belarusian State University. My doctoral work was recognized with the "Lydie and Michel Wittner" research prize in France. In 2020, I joined Prof. Eugenia Kumacheva’s group at the University of Toronto as a postdoctoral fellow, where I developed a microfluidics- and AI-based drug discovery platform for optimizing multidrug regimens with high therapeutic efficacy and low toxicity.
In 2024, I joined the University of Toronto’s Acceleration Consortium as a Staff Scientist, where I lead the development of automation pipelines for accelerated materials and drug discovery. My work integrates AI-driven experimental design with robotics and high-throughput screening, supporting the Consortium’s mission to build self-driving laboratories. I also collaborate across multidisciplinary teams to advance intelligent experimentation in chemistry, nanomedicine, and biotechnology.
In 2019, I completed my Ph.D. in Nanobiotechnology under joint supervision from the University of Lorraine and Belarusian State University. My doctoral work was recognized with the "Lydie and Michel Wittner" research prize in France. In 2020, I joined Prof. Eugenia Kumacheva’s group at the University of Toronto as a postdoctoral fellow, where I developed a microfluidics- and AI-based drug discovery platform for optimizing multidrug regimens with high therapeutic efficacy and low toxicity.
In 2024, I joined the University of Toronto’s Acceleration Consortium as a Staff Scientist, where I lead the development of automation pipelines for accelerated materials and drug discovery. My work integrates AI-driven experimental design with robotics and high-throughput screening, supporting the Consortium’s mission to build self-driving laboratories. I also collaborate across multidisciplinary teams to advance intelligent experimentation in chemistry, nanomedicine, and biotechnology.
Education
Dr. Lina Bezdetnaya
Dr. Vladimir Zorin
Dr. Henry-Pierre Lassalle
Development of a new lipid-based formulation of photosensitizer temoporfin to improve the efficacy of photodynamic therapy in cancer treatment. Exploration of the mechanisms of the formation of inclusion complexes between temoporfin and cyclodextrins through experimental and theoretical methods. Screening of the developed nanoformulation in preclinical cancer models.
Dr. Vladimir Zorin
Dr. Henry-Pierre Lassalle
Development of a new lipid-based formulation of photosensitizer temoporfin to improve the efficacy of photodynamic therapy in cancer treatment. Exploration of the mechanisms of the formation of inclusion complexes between temoporfin and cyclodextrins through experimental and theoretical methods. Screening of the developed nanoformulation in preclinical cancer models.
Dr. Vladimir Zorin
Study of alteration of mTHPC distribution processes in cells and tissues via b-cyclodextrins
Study of alteration of mTHPC distribution processes in cells and tissues via b-cyclodextrins
Dr. Vladimir Zorin
Study of physicochemical methods of distribution analysis of photosensitizer Foscan in biological systems
Study of physicochemical methods of distribution analysis of photosensitizer Foscan in biological systems
Research experience
Prof. Eugenia Kumacheva
Development of a tumor-on-a-chip platform that utilizes microfluidics to test anticancer therapies. By incorporating Artificial Intelligence into this platform, the drug testing process was steamlined, resulting in faster and more accurate results. This innovative approach has the potential to improve cancer drug testing and pave the way toward personalized medicine.
Development of a tumor-on-a-chip platform that utilizes microfluidics to test anticancer therapies. By incorporating Artificial Intelligence into this platform, the drug testing process was steamlined, resulting in faster and more accurate results. This innovative approach has the potential to improve cancer drug testing and pave the way toward personalized medicine.
Dr. Lina Bezdetnaya
Contributed to the industrial research project with Biolitec Research GmbH focused on in vivo testing of lipid-based formulations of the photosensitizer temoporfin. Conducted preclinical experiments to evaluate the permeability of these formulations in vivo
Contributed to the industrial research project with Biolitec Research GmbH focused on in vivo testing of lipid-based formulations of the photosensitizer temoporfin. Conducted preclinical experiments to evaluate the permeability of these formulations in vivo
Dr. Vladimir Zorin
Development of a cyclodextrin-based formulation for delivery of photosensitizer temoporfin
Development of a cyclodextrin-based formulation for delivery of photosensitizer temoporfin
Laboratory Assistant
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Jan 2014 – Jul 2015
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Jan 2014 – Jul 2015
Dr. Vladimir Belevtsev
Worked on a collaborative research project focusing on photodynamic therapy with chlorine e6 derivatives on blood tumor cell lines.
Worked on a collaborative research project focusing on photodynamic therapy with chlorine e6 derivatives on blood tumor cell lines.
Contacts
